EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Establishment of a Common Marmoset Lineage Carrying a Frameshift Mutation in SETD1A , a Schizophrenia Risk Gene

Zefeng Wei, Harumi Nakao, Yuichi Hiraoka, Maria Harbers, Yukiko Abe, Motoki Goto, Moe Tamano, Mai Saeki, Yusuke Kishi iD, Atsu Aiba iD

Journal of Neurochemistry · 2026

DOI: 10.1111/jnc.70546 ↗

At a glance

Journal article in Journal of Neurochemistry, 2026. Written by Zefeng Wei and 9 co-authors. Institution: Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Jap…. Major MEDLINE topics: Histone-Lysine N-Methyltransferase, Frameshift Mutation, Schizophrenia. 29 references. The full text is freely available (open access, CC BY 4.0). Funded by: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Ono Pharmaceutical Foundation for Oncology, Immunology and Neurology.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Appropriate histone modifications are essential for maintaining functional chromatin structure and gene expression, and dysfunction of their regulators has been linked to a variety of diseases. Among these modifications, trimethylation of lysine 4 on histone H3 (H3K4me3) is a well‐characterized epigenetic mark enriched at transcription start sites of actively transcribed genes. H3K4me3 regulates gene transcription by recruiting transcription factors, facilitating chromatin accessibility, and preventing DNA methylation. In mammals, methylation of H3K4 is catalyzed by a family of histone methyltransferases including SET domain containing 1A (SETD1A), which is primarily responsible for genome‐wide deposition of H3K4me2/3. Loss‐of‐function variants in SETD1A , highlighting its critical role in brain development and cognitive function, are strongly associated with schizophrenia (SCZ) and other neurodevelopmental disorders, but the underlying mechanisms remain largely unclear. To better understand the epigenetic and neurobiological consequences of SETD1A dysfunction, non‐human primate models can serve as a useful tool because of their close evolutionary relationship to humans and highly developed cognitive abilities. In this study, we established a genetically engineered common marmoset ( Callithrix jacchus ) lineage carrying a frameshift mutation in SETD1A , which is, to the best of our knowledge, the first non‐human primate lineage carrying a mutation in an epigenetic regulatory gene associated with SCZ, and confirmed germline transmission of the mutant allele. In a comparison between fibroblasts derived from one SETD1A mutant and one wild‐type marmoset, the mutant showed a lower SETD1A protein level, modest differences in H3K4me3 deposition, and broader differences in gene expression profiles. Although these molecular observations require validation using additional biological replicates, the establishment of this SETD1A mutant marmoset lineage provides a valuable platform for bridging molecular mechanisms with primate neurobiology and for investigating the role of epigenetic regulation in the pathophysiology of neuropsychiatric and neurodevelopmental disorders. image

Subjects

MeSH terms (MEDLINE)

Histone-Lysine N-MethyltransferaseFrameshift MutationSchizophreniaAnimalsCallithrixGenetic Predisposition to DiseaseAnimals, Genetically ModifiedHistonesMaleEpigenesis, Genetic

Substances

Histone-Lysine N-MethyltransferaseHistones

Authors and institutions

  • Laboratory of Animal Resources, Center for Disease Biology and Integrative Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Laboratory of Molecular Neurobiology, Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan.
  • Laboratory of Molecular Biology, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
  • Division of Aging Biology, Research Institute for Science and Technology, Tokyo University of Science, Chiba, Japan.

ORCID profiles: Yusuke Kishi, Atsu Aiba

Funding

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • Ono Pharmaceutical Foundation for Oncology, Immunology and Neurology
  • Takahashi Industrial and Economic Research Foundation

Cite

APA

Wei, Z., Nakao, H., Hiraoka, Y., Harbers, M., Abe, Y., Goto, M., Tamano, M., Saeki, M., Kishi, Y., & Aiba, A. (2026). Establishment of a Common Marmoset Lineage Carrying a Frameshift Mutation in SETD1A , a Schizophrenia Risk Gene. Journal of Neurochemistry. https://doi.org/10.1111/jnc.70546

Vancouver

Wei Z, Nakao H, Hiraoka Y, Harbers M, Abe Y, Goto M, et al. Establishment of a Common Marmoset Lineage Carrying a Frameshift Mutation in SETD1A , a Schizophrenia Risk Gene. Journal of Neurochemistry. 2026. doi:10.1111/jnc.70546

BibTeX
@article{Wei2026,
  author = {Wei, Zefeng and Nakao, Harumi and Hiraoka, Yuichi and Harbers, Maria and Abe, Yukiko and Goto, Motoki and Tamano, Moe and Saeki, Mai and Kishi, Yusuke and Aiba, Atsu},
  title = {Establishment of a Common Marmoset Lineage Carrying a Frameshift Mutation in SETD1A , a Schizophrenia Risk Gene},
  journal = {Journal of Neurochemistry},
  year = {2026},
  doi = {10.1111/jnc.70546}
}
Start for free →